ADELAIDE, Australia / RankWire.AI / – A groundbreaking discovery by Australian medical scientists reveals a molecular switch that influences the progression of aggressive tumors, opening potential avenues for therapy aimed at preventing secondary cancers. Published in EMBO Molecular Medicine, researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that boosting levels of a crucial regulatory molecule known as miR-342 can significantly decrease tumor dissemination. Their results point to a promising new method to combat triple-negative breast cancer by targeting dormant cancer cells before they develop into life-threatening metastases in distant organs.
While triple-negative breast cancer represents 10% to 15% of the approximately 21,000 annual breast cancer cases in Australia, it is responsible for a disproportionate share of fatalities. This subtype lacks estrogen, progesterone, and HER2 receptors, making standard hormone-targeted treatments ineffective. The lead scientists demonstrated that diminished miR-342 levels activate a cancer-promoting pathway called E2F, which enables dormant cancer cells to metastasize and form dangerous secondary tumors throughout the body.
Targeted Treatments Offer Renewed Hope for Preventing High-Risk Metastasis
In laboratory models, re-establishing miR-342 levels notably suppressed the spread of cancer to distant sites. Additionally, scientists found that palbociclib, an already approved CDK4/6 inhibitor used for hormone receptor-positive breast cancers, effectively impeded metastatic tumor growth in models with low miR-342. These results suggest that assessing miR-342 levels could enable clinicians to repurpose existing drugs for high-risk patients, enhancing treatment strategies.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, reaffirmed that the main obstacle in treating aggressive breast cancers is preventing metastasis. Gregory explained that since palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread can stop microscopic deposits from enlarging. This approach shifts focus from merely reducing primary tumor size to preventing the development of secondary cancers that could become life-threatening.
Pre-Clinical Data Featured in Peer-Reviewed EMBO Molecular Medicine
The research team highlighted that the biological diversity of triple-negative breast cancer has long complicated the creation of universal targeted treatments. By identifying a shared biological vulnerability within a specific patient subgroup, their study paves the way for personalized treatment options. As Australian scientists work to validate these findings using patient-derived models, preparations are underway for clinical trial phases.
Australian cancer research organizations and medical oncologists expressed strong support for the study, emphasizing the urgent need for expanded treatment options when primary therapies do not succeed. The team intends to partner with international clinical networks to expedite biomarker screening efforts. Confirming the effectiveness of miR-342 testing could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor therapy during early intervention stages.